Transient Removal of CD46 Is Safe and Increases B-cell Depletion by Rituximab in CD46 Transgenic Mice and Macaques

We have developed a technology that depletes the complement regulatory protein (CRP) CD46 from the cell surface, and thereby sensitizes tumor cells to complement-dependent cytotoxicity triggered by therapeutic monoclonal antibodies (mAbs). This technology is based on a small recombinant protein, Ad3...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Beyer, Ines, Cao, Hua, Persson, Jonas, Wang, Hongjie, Liu, Ying, Yumul, Roma, Li, Zongyi, Woodle, Douglas, Manger, Ronald, Gough, Michael, Rocha, Diane, Bogue, Jaclyn, Baldessari, Audrey, Berenson, Ronald, Carter, Darrick, Lieber, André
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Nature Publishing Group 2013
Θέματα:
Original Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3594032/
https://ncbi.nlm.nih.gov/pubmed/23089733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2012.212
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια